Spermosens AB (publ) is listed on Spotlight Stock Market
The share is traded under the ticker SPERM and ISIN-code SE0015346424
Aktieägarna i Spermosens AB (publ), org.nr 559179-0380 (”Bolaget”), kallas till extra bolagsstämma den 17 februari 2025 kl. 15.00 i Bolagets lokaler på Medicon Village Scheeletorget 1, 223 81 i Lund.
Read more at CisionSpermosens AB (“Spermosens” or the “Company”) announces that it is relocating to a smaller office within Medicon Village, The Spark. While the Company retains its existing address, this move is part of its continued commitment to operational efficiency and cost-consciousness.
Read more at CisionSpermosens AB (“Spermosens” or the “Company”) provides a year-end update on its progress in 2024, a transformative year marked by key achievements, new leadership and the execution of a revised strategy that has positioned the Company for success going forward.
Read more at CisionNOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE The rights…
Read more at CisionNOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, HONG KONG, SOUTHKOREA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA OR BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The Board…
Read more at CisionSpermosens AB ("Spermosens" or the "Company") is pleased to announce the first interim results from its ongoing clinical study aimed at validating the diagnostic value of the patented JUNO-Checked system. The study is progressing as planned, and the first results are now being presented according to schedule. The first interim results from the clinical study…
Read more at CisionEminova Fondkommission AB
Biblioteksgatan 3, 3 tr.
111 46 Stockholm
Tel: +46 8 684 211 00
info@eminova.se